Braxia Scientific Announces Symbol Change on OTC Markets to BRAXF prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies
Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment
TORONTO, May 20, 2021 /PRNewswire/ - Braxia Scientific Corp. ( Braxia Scientific or the Company ), (CSE: BRAX) (FWB: 496) (OTC: SHRMF), a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the launch of the Braxia Institute ( Braxia Institute ), the Company s training Centre of Excellence focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment t
Over 200 physicians and healthcare providers from Canada U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and … Over 200 physicians and healthcare providers from Canada , U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment
Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia s Symposium on Rapid Acting Anti-Depressants prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Compass Pathways (NASDAQ:CMPS) and
MindMed (NASDAQ:MNMD) remain the only two companies in psychedelics to reach a major U.S. stock exchange. Both companies presented net losses associated with R&D expenses, as entities in the space race towards gaining ground in a sector that still hasn’t reached early maturity or profitability.
Both companies presented strong cash positions to advance their research pipelines.
Compass, Pressing On Psilocybin: Compass highlighted the issuing of two new patents and a post-quarter equity financing round of $144 million.